Paloma Diaz‐Fernandez
Paloma Diaz‐Fernandez has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Gary Finka
Biopharm Process Research, Biopharm Product Development and Supply GlaxoSmithKline R&D Stevenage UK
3 shared publications- Antonio Benedetti
Process Engineering & Analytics, Product Development and Supply GlaxoSmithKline R&D Stevenage UK
2 shared publications - Daniel C. Sevin
Target Discovery GlaxoSmithKline 69117 Heidelberg Germany
2 shared publications - Fabrizio Bezzo
CAPE‐Lab – Computer‐Aided Process Engineering Laboratory, Department of Industrial Engineering University of Padova Padova ITALY
2 shared publications - Gianmarco Barberi
CAPE‐Lab – Computer‐Aided Process Engineering Laboratory, Department of Industrial Engineering University of Padova Padova ITALY
2 shared publications - Johanna Vappiani
GlaxoSmithKline R&D, Cellzome GmbH, Meyerhofstrasse 1, Heidelberg 69117, Germany
2 shared publications
Latest Publications
- Open Access
- 9 October 2024
- Published by Wiley in AIChE Journal
- Vol. 71 (2)
Productive CHO cell lines selection in biopharm process development through machine learning on metabolomic dynamics
The identification of highly productive cell lines is crucial in the development of bioprocesses for the production of therapeutic monoclonal antibodies (mAbs). Metabolomics data provide valuable information for cell line selection and allow the study of the relationship with mAb productivity and product quality attributes. We propose a novel robust machine learning procedure which, exploiting dynamic metabolomic data from the Ambr®15 scale, supports the selection of highly productive cell lines during biopharmaceutical bioprocess development and scale‐up. The metabolomic profiles dynamics allows to identify the cell lines with high productivity, already in the early stages of experimentation, and the biomarkers that are the most related to mAb productivity, finding at the same time the key metabolic pathways for discriminating mAb productivity. Specifically, tricarboxylic acid cycle pathways are predominant in the early stages of the cultivation, while amino and nucleotide sugar pathways influence in the late stages of the culture.
- 9 October 2024
- Published by Wiley in AIChE Journal
- Vol. 71 (2)
Open AccessProductive CHO cell lines selection in biopharm process development through machine learning on metabolomic dynamics
The identification of highly productive cell lines is crucial in the development of bioprocesses for the production of therapeutic monoclonal antibodies (mAbs). Metabolomics data provide valuable information for cell line selection and allow the study of the relationship with mAb productivity and product quality attributes. We propose a novel robust machine learning procedure which, exploiting dynamic metabolomic data from the Ambr®15 scale, supports the selection of highly productive cell lines during biopharmaceutical bioprocess development and scale‐up. The metabolomic profiles dynamics allows to identify the cell lines with high productivity, already in the early stages of experimentation, and the biomarkers that are the most related to mAb productivity, finding at the same time the key metabolic pathways for discriminating mAb productivity. Specifically, tricarboxylic acid cycle pathways are predominant in the early stages of the cultivation, while amino and nucleotide sugar pathways influence in the late stages of the culture.
- 14 April 2022
- Published by Elsevier in Metabolic Engineering
- Vol. 72, 353-364
Integrating metabolome dynamics and process data to guide cell line selection in biopharmaceutical process development
- 14 April 2022
- Published by Elsevier in Metabolic Engineering
- Vol. 72, 353-364
Integrating metabolome dynamics and process data to guide cell line selection in biopharmaceutical process development
- 31 August 2020
- Published by Wiley in Biotechnology Progress
- Vol. 37 (1) , e3074
Spectroscopy integration to miniature bioreactors and large scale production bioreactors–Increasing current capabilities and model transfer
Spectroscopy techniques are being implemented within the biopharmaceutical industry due to their non‐destructive ability to measure multiple analytes simultaneously, however, minimal work has been applied focussing on their application at small scale. Miniature bioreactor systems are being applied across the industry for cell line development as they offer a high‐throughput solution for screening and process optimization. The application of small volume, high‐throughput, automated analyses to miniature bioreactors has the potential to significantly augment the type and quality of data from these systems and enhance alignment with large‐scale bioreactors. Here, we present an evaluation of 1. a prototype that fully integrates spectroscopy to a miniature bioreactor system (ambr®15, Sartorius Stedim Biotech) enabling automated Raman spectra acquisition, 2. In 50 L single‐use bioreactor bag (SUB) prototype with an integrated spectral window. OPLS models were developed demonstrating good accuracy for multiple analytes at both scales. Furthermore, the 50 L SUB prototype enabled on‐line monitoring without the need for sterilization of the probe prior to use and minimal light interference was observed. We also demonstrate the ability to build robust models due to induced changes that are hard and costly to perform at large scale and the potential of transferring these models across the scales. The implementation of this technology enables integration of spectroscopy at the small scale for better process understanding and generation of robust models over a large design space while facilitating model transfer throughout the scales enabling continuity throughout process development and utilization and transfer of ever‐increasing data generation from development to manufacturing.
- 31 August 2020
- Published by Wiley in Biotechnology Progress
- Vol. 37 (1) , e3074
Spectroscopy integration to miniature bioreactors and large scale production bioreactors–Increasing current capabilities and model transfer
Spectroscopy techniques are being implemented within the biopharmaceutical industry due to their non‐destructive ability to measure multiple analytes simultaneously, however, minimal work has been applied focussing on their application at small scale. Miniature bioreactor systems are being applied across the industry for cell line development as they offer a high‐throughput solution for screening and process optimization. The application of small volume, high‐throughput, automated analyses to miniature bioreactors has the potential to significantly augment the type and quality of data from these systems and enhance alignment with large‐scale bioreactors. Here, we present an evaluation of 1. a prototype that fully integrates spectroscopy to a miniature bioreactor system (ambr®15, Sartorius Stedim Biotech) enabling automated Raman spectra acquisition, 2. In 50 L single‐use bioreactor bag (SUB) prototype with an integrated spectral window. OPLS models were developed demonstrating good accuracy for multiple analytes at both scales. Furthermore, the 50 L SUB prototype enabled on‐line monitoring without the need for sterilization of the probe prior to use and minimal light interference was observed. We also demonstrate the ability to build robust models due to induced changes that are hard and costly to perform at large scale and the potential of transferring these models across the scales. The implementation of this technology enables integration of spectroscopy at the small scale for better process understanding and generation of robust models over a large design space while facilitating model transfer throughout the scales enabling continuity throughout process development and utilization and transfer of ever‐increasing data generation from development to manufacturing.